Hepatitis B Vaccine (Recombinant) Completed Phase 3 Trials for Viral Hepatitis B / Infants / Healthy Volunteers Prevention

IndicationsStatusPurposePhase
CompletedPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT00435812Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine
NCT01251276Hepatitis B Challenge Dose in Adults (V232-059-10)
NCT01463683Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
NCT02697474Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.
NCT00383591Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
NCT00383383Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
NCT00393523Hepatitis B Vaccine Booster Study (V232-058)
NCT00414050A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants
NCT00440531Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)
NCT00697242Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults
NCT00697840Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B
NCT00697970Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine
NCT00697931Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders
NCT00698087Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B
NCT02152709Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine
NCT01005407Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
NCT02117934Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine